AstraZeneca to invest $2 billion in Maryland manufacturing expansion
The multibillion-dollar Maryland expansion is part of AstraZeneca’s sweeping $50 billion global investment plan
The multibillion-dollar Maryland expansion is part of AstraZeneca’s sweeping $50 billion global investment plan
Innovent plans to soon submit a new drug application (NDA) to China’s National Medical Products Administration
HER2-mutant NSCLC typically has a poor prognosis and limited treatment options
The full approval is based on the results from the pivotal Phase 3 EPCORE FL-1 study
The X CUBE 50 integrates ALPINION’s advanced X+ Architecture
The study successfully met its primary endpoint, demonstrating similar rates of viral suppression for DOR/ISL compared to Biktarvy at 48 weeks
This is the first and only subcutaneous immune checkpoint inhibitor available in Europe
Grangemouth serves as PPS’s dedicated antibody-drug conjugate development and manufacturing hub
Subscribe To Our Newsletter & Stay Updated